Cargando…
The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318704/ https://www.ncbi.nlm.nih.gov/pubmed/31587373 http://dx.doi.org/10.1111/jdv.16003 |
_version_ | 1783550914253029376 |
---|---|
author | de Bruin‐Weller, M. Gadkari, A. Auziere, S. Simpson, E.L. Puig, L. Barbarot, S. Girolomoni, G. Papp, K. Pink, A.E. Saba, G. Werfel, T. Eckert, L. |
author_facet | de Bruin‐Weller, M. Gadkari, A. Auziere, S. Simpson, E.L. Puig, L. Barbarot, S. Girolomoni, G. Papp, K. Pink, A.E. Saba, G. Werfel, T. Eckert, L. |
author_sort | de Bruin‐Weller, M. |
collection | PubMed |
description | BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient‐Oriented‐Scoring of Atopic Dermatitis (PO‐SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. RESULTS: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD. |
format | Online Article Text |
id | pubmed-7318704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73187042020-06-29 The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada de Bruin‐Weller, M. Gadkari, A. Auziere, S. Simpson, E.L. Puig, L. Barbarot, S. Girolomoni, G. Papp, K. Pink, A.E. Saba, G. Werfel, T. Eckert, L. J Eur Acad Dermatol Venereol Allergy and Eczema BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient‐Oriented‐Scoring of Atopic Dermatitis (PO‐SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. RESULTS: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD. John Wiley and Sons Inc. 2020-01-14 2020-05 /pmc/articles/PMC7318704/ /pubmed/31587373 http://dx.doi.org/10.1111/jdv.16003 Text en © 2019 Sanofi. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Allergy and Eczema de Bruin‐Weller, M. Gadkari, A. Auziere, S. Simpson, E.L. Puig, L. Barbarot, S. Girolomoni, G. Papp, K. Pink, A.E. Saba, G. Werfel, T. Eckert, L. The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title | The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title_full | The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title_fullStr | The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title_full_unstemmed | The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title_short | The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada |
title_sort | patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in europe and canada |
topic | Allergy and Eczema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318704/ https://www.ncbi.nlm.nih.gov/pubmed/31587373 http://dx.doi.org/10.1111/jdv.16003 |
work_keys_str_mv | AT debruinwellerm thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT gadkaria thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT auzieres thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT simpsonel thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT puigl thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT barbarots thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT girolomonig thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT pappk thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT pinkae thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT sabag thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT werfelt thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT eckertl thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT debruinwellerm patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT gadkaria patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT auzieres patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT simpsonel patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT puigl patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT barbarots patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT girolomonig patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT pappk patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT pinkae patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT sabag patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT werfelt patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada AT eckertl patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada |